NCT02648997View on ClinicalTrials.gov

An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2025

Conditions

Meningiomas

Interventions

DRUG

Nivolumab - 240 mg

240 mg every 2 weeks

DRUG

Ipilimumab - 1 mg/kg

1 mg/kg every 3 weeks

DRUG

Nivolumab - 480 mg

480 mg once every 4 weeks

DRUG

Nivolumab - 3 mg/kg

3 mg/kg every 3 weeks

RADIATION

External Beam RT

IMRT, 3D-CRT, or proton-beam radiation therapy

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT02648997 - An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma | Biotech Hunter | Biotech Hunter